Loading…
Based on limited metadata, this warning letter addresses Jiangsu NHWA Pharmaceutical Co., Ltd., a pharmaceutical manufacturer, regarding drug manufacturing or quality issues. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined, though FDA warning letters typically cite concerns such as manufacturing practices, product quality, labeling, or regulatory compliance deficiencies. The letter was issued by the FDA in September 2019 and applies to the company's drug products, though the specific issuing office is not identified in the available metadata.